



## MAYNE PHARMA ANNOUNCES NEW DISTRIBUTERx PARTNERSHIP WITH RESILIA PHARMACEUTICALS

**1 June 2026, Adelaide, Australia:** Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX:MYX), today announces the Company's wholly owned subsidiary, DistributeRx LLC (DistributeRx), has entered into its first third party partnership with Resilia Pharmaceuticals to exclusively distribute RECEDO® topical gel through DistributeRx's streamlined prescription distribution platform to expand patient access to this innovative treatment. RECEDO® is among the most widely recommended scar gels and wound healing agents in the United States. Under the terms of the agreement, DistributeRx will receive a fixed fee for each RECEDO® prescription filled using the DistributeRx solution, which is expected to deliver the most cost-effective outcome for the product and patients.

RECEDO® topical gel is intended for the management of old and new hypertrophic or keloid scarring resulting from burns, general surgical procedures or trauma wounds.

Resilia Pharmaceuticals, Inc®. is an Atlanta, Georgia-based pharmaceutical company dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products ([www.resiliapharma.com](http://www.resiliapharma.com)).

**Mr Daniel Moore, President of DistributeRx commented** *"We are pleased to enter into this agreement with Resilia Pharmaceuticals for the distribution of RECEDO® topical gel. Scar management is a category where patients have historically had limited effective options, and the RECEDO® profile positions it well to meet that demand. DistributeRx is well placed to accelerate its commercial reach. We look forward to working with more manufacturers into the future to assist them with patient reach and access through our unique and scalable platform, which continues to show significant growth, ahead of expectations, after three months following our launch."*

**Mr Harsha Murthy, Executive Chairman of the Board of Resilia Pharmaceuticals said** *"DistributeRx brings the commercial infrastructure and market reach that RECEDO® deserves. This partnership is an important step in Resilia's plans to expand RECEDO®'s use among prescribers, especially in plastic surgery (such as Mohs surgery procedures) and OBGYN (post-Caesarean section treatment), thereby ensuring more patients across the United States have access to a proven, prescription-grade scar management solution. We look forward to building a strong, mutually beneficial and lasting commercial relationship with DistributeRx and Mayne Pharma."*

### For further information contact:

Dr Tom Duthy  
Investor Relations  
+61 402 493 727  
[ir@maynepharma.com](mailto:ir@maynepharma.com)

Authorised for release to the ASX by the Board Chair.

RECEDO® is a trademark of a third party.

### Mayne Pharma Group Limited

ABN 76 115 832 963

[maynepharma.com](http://maynepharma.com)

1538 Main North Road, Salisbury South, SA 5106 Australia

For personal use only





## Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)

## About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](http://maynepharma.com).

## About DistributeRx

DistributeRx is a healthcare solutions company that partners with manufacturers to streamline the prescription distribution process and expand patient access to medications. From strategic access programs and product support to streamlined pharmacy services, DistributeRx is committed to improving product accessibility for prescribers and patients and driving success. DistributeRx is a wholly owned subsidiary of Mayne Pharma.

For personal use only

